Cosmos Health (NASDAQ:COSM) CEO Grigorios Siokas Purchases 218,447 Shares

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas purchased 218,447 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were purchased at an average cost of $0.21 per share, for a total transaction of $45,873.87. Following the transaction, the chief executive officer directly owned 13,481,808 shares of the company’s stock, valued at approximately $2,831,179.68. The trade was a 1.65% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Grigorios Siokas also recently made the following trade(s):

• On Wednesday, June 10th, Grigorios Siokas purchased 701,447 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.23 per share, for a total transaction of $161,332.81.

Cosmos Health Stock Performance

Shares of COSM opened at $0.21 on Friday. The stock has a market capitalization of $13.04 million, a P/E ratio of -0.33 and a beta of 4.79. The firm’s fifty day simple moving average is $0.30 and its two-hundred day simple moving average is $0.40. The company has a current ratio of 1.08, a quick ratio of 0.92 and a debt-to-equity ratio of 0.31. Cosmos Health Inc. has a 12 month low of $0.20 and a 12 month high of $1.32.

Cosmos Health (NASDAQ:COSM) last released its quarterly earnings data on Thursday, May 21st. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.06). The company had revenue of $18.40 million for the quarter, compared to analysts’ expectations of $17.93 million. Cosmos Health had a negative net margin of 30.41% and a negative return on equity of 52.85%. As a group, analysts predict that Cosmos Health Inc. will post -0.06 EPS for the current year.

Key Headlines Impacting Cosmos Health

Here are the key news stories impacting Cosmos Health this week:

• Positive Sentiment: The company reported annualized sales above $1.5 million for its C-Scrub and C-Sept antiseptic brands in the UK and Greece, and outlined EU expansion plans that could target $7.4 million in revenue and $5.3 million in gross profit by 2028. Article Title
• Positive Sentiment: Cosmos Health announced new contract manufacturing orders totaling 253,657 units, adding to evidence that its Cana subsidiary is seeing steady commercial demand across multiple medicines and pharmaceutical products. Article Title
• Positive Sentiment: CEO Grigorios Siokas made additional open-market share purchases, which investors often view as a signal of management confidence in the company’s outlook. Article Title
• Positive Sentiment: The company signed a letter of intent to acquire Doc Pharma S.A., a GMP manufacturer, a move that could expand assets, production capacity, margins, and its product portfolio if completed. Article Title

Hedge Funds Weigh In On Cosmos Health

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its position in shares of Cosmos Health by 16.7% during the 1st quarter. Renaissance Technologies LLC now owns 390,500 shares of the company’s stock worth $124,000 after purchasing an additional 55,925 shares in the last quarter. XTX Topco Ltd boosted its position in shares of Cosmos Health by 52.1% during the 4th quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock worth $50,000 after purchasing an additional 34,117 shares in the last quarter. Finally, Citadel Advisors LLC boosted its position in shares of Cosmos Health by 133.1% during the 3rd quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock worth $250,000 after purchasing an additional 128,776 shares in the last quarter. Institutional investors own 12.61% of the company’s stock.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.